MOLECULAR CYTOGENETICS OF SOLID TUMORS

这一医生-科学家奖将使弗莱彻博士获得广泛的 并在实验细胞遗传学和 分子生物学。在颁奖的每个阶段，这些技能将是 适用于肿瘤学领域的特定研究问题。第一阶段 将由辛西娅·C·莫顿博士和 病理学和遗传学系的菲利普·莱德，分别在 哈佛医学院。此阶段的主要重点将是本地化 新生基底细胞癌综合征的致病基因。在阶段中 我，弗莱彻博士还将参加哈佛大学的研讨会和课程 在医学院和杰克逊实验室，并将继续广泛 实体肿瘤细胞遗传学研究进展。实体瘤细胞遗传学 项目将包括：1)鉴定特征染色体 特定恶性肿瘤中的重排；2)诊断的研究 特殊细胞遗传学模式在间叶性肿瘤中的意义； 成人遗传不稳定程度和作用的测定 恶性肿瘤。 塞缪尔·E·勒克斯博士，世界卫生组织血液肿瘤科主任 波士顿儿童医院和史蒂文·J·布拉科夫博士，科长 达纳-弗雷伯癌症研究所的儿科肿瘤学将共同发起第二阶段 这个奖项的获得者。在第二阶段，弗莱彻博士将建立一个实验室 致力于实体肿瘤的细胞遗传学和分子特征研究 在达纳-法伯癌症研究所。这个实验室将利用 细胞遗传学发现作为后续分子研究的基础 实体肿瘤的病因。

This physician-Scientist Award will enable Dr. Fletcher to acquire a broad and thorough training in the fields of experimental cytogenetics and molecular biology. In each phase of the award, these skills will be applied to specific research questions in the field of oncology. Phase I will be conducted under the co-sponsorship of Drs. Cynthia C. Morton and Philip Leder, in the Department of Pathology and Genetics, respectively, at Harvard Medial School. A primary focus of this phase will be to localize the causative gene for nevoid basal cell carcinoma syndrome. During Phase I, Dr. Fletcher will also participate in seminars and courses at Harvard Medical School and at the Jackson Laboratory, and will continue extensive work-in-progress on solid tumor cytogenetics. The solid tumor cytogenetics projects will include: 1) identification of characteristic chromosome rearrangements in specific malignancies; 2) investigation of the diagnostic significance of specific cytogenetic patterns in mesenchymal tumors; and 3) determination of the extent and role of genetic instability in adult malignancies. Dr. Samuel E. Lux, Chief of the Hematology-Oncology Division at The Children's Hospital, Boston, and Dr. STeven J. Burakoff, Chief, Division of Pediatric Oncology, Dana-Fraber Cancer Institute, will co-sponsor Phase II of this award. During Phase II, Dr. Fletcher will establish a laboratory devoted to the cytogenetic and molecular characterization of solid tumors at the Dana-Farber Cancer Institute. This laboratory will utilize cytogenetic findings as a basis for subsequent molecular investigations into the etiologies of solid tumors.